I usually have a lot to say. I just know when to keep it to myself.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TTGL Chart:
TTGL.OB 2.14 Titan Global Holdings Announces $15 Million Sale Leaseback Transaction of Appalachian Oil Company Real Estate
Thursday September 6, 3:30 am ET
Simultaneous Sale of Appco Real Estate to Institutional Investor in Leaseback Transaction to Substantially De-leverage Company's Appco Acquisition
Shares Outstanding: 49.04M
Float: 13.14M
DALLAS--(BUSINESS WIRE)--Titan Global Holdings, Inc. (OTCBB:TTGL - News), a high-growth diversified holding company, announced today that in connection with its planned acquisition of Appalachian Oil Company, Inc. ("Appco"), Titan and an institutional investor ("Buyer") reached an agreement in principal wherein the Buyer will pay $15 million for the 13 properties owned and operated by Appco and four properties owned by Appco but leased to third parties simultaneous with Titan's acquisition of Appco.
Titan and the sellers of Appco agreed to a closing date of September 12, 2007.
Under the Appco purchase agreement, Titan is to pay Appco's sellers $30 million in cash and assume certain debts. The sale leaseback transaction of Appco's real estate will substantially de-leverage Titan's acquisition of Appco by reducing approximately half its cash requirements to close the transaction. Under the terms of the leaseback, Appco will lease the properties on a conventional twenty-year term with extension options.
Appco will be the first acquisition of the Company's recently announced Titan Global Energy, which has been formed to aggregate underutilized assets that can provide significant opportunities for revenue and earnings growth, such as the continued vertical integration of the supply chain, as well as future acquisitions to complement Appco's existing retail and wholesale distribution footprint.
Titan's management anticipates Appco will generate record revenues in excess of $410 million with increased positive cash flow for the fiscal year ended September 30, 2007. Appco generated $403 million in revenue and was positive cash flow in its fiscal year 2006. Titan projects Appco will maintain or grow revenue from $410 million and generate stronger cash flow and margins for fiscal 2008 as it increases the distribution of biofuels through its established distribution channels. The extent of the improvement in Appco's cash flow and margins will be subject, among other things, to the availability and deployment of such biofuels which Titan's management is confident that it is poised to fully exploit.
Titan intends to further Appco's penetration into the ethanol market through the distribution of biodiesel products. These strategies can increase Appco's margins while aiding in the protection and preservation of our environment.
Appco, formed in 1923 and based in Blountville, Tennessee, is a privately held petroleum company that owns and operates an extensive petroleum product distribution network. Appco distributes petroleum products to more than 160 dealers in the southeastern United States and owns and operates 56 convenience store locations. Appco has more than 550 employees and maintains long-standing partnerships with strategic terminal operators and major oil companies.
"I have extensive experience in the real estate leaseback space," said David Marks, Chairman of Titan Global Holdings. "In an effort to de-leverage the acquisition for Titan, strategic Titan investor Frank Crivello and I have structured a leaseback transaction with an institutional investor. We anticipate closing that transaction simultaneously with Titan's closing of Appco. This is a classic win-win transaction for the Company, the institutional investor and ultimately for Titan shareholders."
The Buyer has reached an agreement in principal to hire Mr. Marks as the unsalaried President of the special purpose entity that will acquire the real estate. In connection with the management and re-sale of the real estate, Phoenix Investors, LLC, a real estate investment and management firm managed by Mr. Marks, will be retained as a consultant. Under the consulting agreement, Phoenix Investors will be compensated with 20% of the net profits from the eventual re-sale of the properties purchased from Appco as realized.
"I am so pleased that David and Frank were able to engineer this leaseback transaction for Titan. Given our opportunities for growth, be it acquisitions or organic growth, real estate isn't the best place for us to invest or tie up our capital," said Bryan Chance, President and Chief Executive Officer of Titan Global Holdings. "With this transaction, which will close simultaneously with our purchase of Appco, we have substantially cut our cash needs. This makes an already compelling transaction exceptional."
About Titan Global Holdings
Titan Global Holdings, Inc. is a high-growth diversified holding company with a dynamic portfolio of companies engaged in emerging telecommunications markets, advanced technologies and energy. In its last fiscal year Titan generated in excess of $109 million in revenues on a consolidated basis.
Titan's Oblio Telecom Inc. ("Oblio") telecommunications subsidiary, based in Richardson, Texas, is a market leader in prepaid telecommunications products and the second largest publicly-owned international telecommunications company focused on the prepaid space. Oblio leverages strategic agreements with Tier 1 telecommunications leaders Sprint and Level3 to supply its brand-name prepaid calling cards. Annually Oblio sells an estimated 35 million of its brand-name prepaid calling cards through its established distribution channels estimated at more than 60,000 retail outlets.
Titan Wireless, Inc. ("T Wireless") is Titan's wireless subsidiary and is a mobile virtual network operator ("MVNO"). T Wireless sells its MVNO prepaid wireless products and wireless services through Oblio's established distribution channels. Titan's Electronics and Homeland Security division specializes in advanced manufacturing processes to provide commercial production runs and quick-turn delivery of printed circuit board prototypes for high-margin markets including Homeland Security and high-tech clients.
For more information, please visit: www.titanglobalholdings.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/titan/ or http://www.b2i.us/irpass.asp?BzID=1314&to=ea&s=0. To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/titan/quote.html. To view an investor fact sheet about the company, visit http://www.trilogy-capital.com/tcp/titan/factsheet.html.
Forward-Looking Statements
Safe Harbor Statement Under the Private Securities Litigation Act of 1995 -- With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of TTGL could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rate and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors see the risk factors associated with our Company, review our SEC filings.
Contact:
Trilogy Capital Partners
Financial Communications:
Ryon Harms, Toll-free: 800-592-6067
ryon@trilogy-capital.com
--------------------------------------------------------------------------------
Source: Titan Global Holdings, Inc.
http://biz.yahoo.com/bw/070906/20070906005267.html?.v=1
i don't have one. Nice to see they cut 200 bucks off though. I still really don't have a use for it.
Does anyone here rave about how great it is? I haven't met anyone who got on board the iphone craze. Hope it was worth it.
I recall the first few minutes, people were taping themselves smashing them to get going on it.
Then this kid had some time on his hands, lol.
a 17-year-old kid in New Jersey—
After a rash of reports over the weekend of hackers who managed to unlock the iPhone—ranging from the iPhoneSIMFree.com team to a 17-year-old kid in New Jersey—AT&T has unsurprisingly decided to rain on the parade, with a little help from its legal team.
Gizmodo is reporting that AT&T has fired off a warning to a group that was planning to sell its iPhone unlocking software. In a press release, a spokesman for iphoneunlocking.com said that AT&T contacted the site early Saturday, warning that the group would run afoul of copyright laws if it went ahead with its planned sale of the software package. The site has decided to hold off releasing the iPhone-unlocking app for now, the spokesman said.
So, all this begs the question: is it legal to unlock the iPhone? Engadget asked a copyright lawyer that very question, and got a rather nuanced answer. According to the attorney, iPhone unlockers are most likely protected by an exception in the DMCA (a law that prohibits the cracking of DRM schemes) that lets you unlock your own phone for the "sole purpose" of using it "lawfully" on a cellular network. However, you can't unlock a phone (including the iPhone) and then sell it; also, Apple and AT&T are free to sue you on the basis of other laws besides the DMCA (and they certainly have the resources—and the incentive—to do so). Bottom line? The lawyer seems to believe that you're probably in the clear as long as you're just unlocking your own iPhone and not selling it on Craigslist; then again, there's no telling what Apple and AT&T have up their legal sleeves. Also, on a practical note, keep in mind that unlocking the phone will probably violate your warranty, so if anything goes wrong, don't look for sympathy from the Apple Genius Bar.
http://tech.yahoo.com/blogs/patterson/4903?comment_start=7&comment_count=20
I believe a 17 year old cracked the code. He traded his secrets for a car.
No joke. Every time I read "Earnings Surprise" I picture a room full of folks with party hats jumping out and yelling
"SURPRISE!!!!!!!!!!!"
You should use this dude on the site:
cha ching SLXP:
Salix Pharmaceuticals Acquires Patent-Protected Metoclopramide-Zydis(R)
Wednesday September 5, 7:03 am ET
Zydis(R) Technology Provides Fast-Dissolving, Patient-Friendly Formulation
http://biz.yahoo.com/bw/070905/20070905005201.html?.v=1
Apple Inc. slashed the price of the top iPhone by $200 Wednesday to bolster holiday sales, but also angered loyal customers who paid top dollar in the gadget's first 10 weeks on the market.
OUCH! Ace Finds $154M Accounting Shortfall
Wednesday September 5, 9:09 pm ET
By Dave Carpenter, AP Business Writer
AP Newsbreak: Ace Hardware Finds $154M Accounting Shortfall on Its Books
CHICAGO (AP) -- Ace Hardware Corp. discovered an approximately $154 million shortfall on its books while preparing to convert from retailer-owned cooperative to for-profit corporation and likely will have to restate its financial results for the last five years, President and CEO Ray Griffith said Wednesday.
Ace has called off the conversion plan and hired an audit consulting firm to help rectify an accounting problem which appears to date to 2002, Griffith told The Associated Press. The company may have to forego returning profits to store owners this year as a result, he said.
He said no money or inventory is missing but the Oak Brook, Ill.-based company has not been able to determine the source of what he characterized as a "significant accounting error."
Ace notified the dealers who own its 4,600 stores of the problem in letters Wednesday from Griffith and its board of directors.
The chief executive said an internal review of the company's financial documents found that its inventory total is $154 million less than its general ledger balance -- the company's primary method for recording its financial transactions. The final total is expected to be somewhat less.
He said the error amounts to "an overstatement of gross margin that resulted in an overstatement of gross profits that resulted in an overpayment of patronage dividends."
"There is no missing money, there is no missing inventory, there is no evidence of theft," Griffith said in a telephone interview. "Obviously we're upset, but we feel very confident that it's a manageable situation and that our business is sound. We're still a very viable business, our comp sales are doing well. This is an accounting issue."
The company's board of directors hired Protiviti Inc., he said, to find and reconcile the error.
Griffith said he was first informed of the problem on Aug. 16 by Ron Knutson, Ace's vice president of finance, and Art McGivern, senior vice president for legal affairs. Plans for the conversion, which were announced two weeks later, went ahead while Ace executives continued looking for the source of the error.
"I immediately thought it was simply a balance sheet issue, a mistake that we would find," Griffith said. "There was probably a little bit of denial there."
He said in the letter to store owners that Ace may hold back "most or all" of its profits this year that it normally distributes to store owners as patronage dividends, considering them to have been paid previously and erroneously. Retailers received $108.8 million through that practice last year.
"This issue will not impact Ace's ability to provide you with the merchandise and services you expect from Ace; we will continue serving all of our retailers as we do today," he assured them.
Ace's bankers have been informed and have pledged their financial support, Griffith said.
The company's auditing for the years in question was performed by KPMG LLP. KPMG spokesman Dan Ginsburg said the company could not comment due to client confidentiality.
Ace's directors said in their letter that the board was "extremely disappointed" to learn about the financial reporting error.
"Ace's finance staff, seasoned management team, internal audit department and even the external auditors engaged by the board failed to detect this error as it built over the last several years," they said.
The 83-year-old hardware chain, which has been a retailer-owned cooperative since the 1970s, had its best sales year since 1998 last year with wholesale sales up 6.5 percent to $3.4 billion. Its stores, about two-thirds owned by independent dealers, racked up almost $12 billion in retail sales.
The hardware business is now dominated, however, by Home Depot Inc. and Lowe's Cos., the two home improvement store chains that had a combined $138 billion in sales last year.
http://www.acehardware.com
http://biz.yahoo.com/ap/070905/ace_hardware_accounting.html?.v=6
IPO Calendar - All Upcoming IPOs
All IPOs On Deck
Company Name
Symbol Underwriter Price Range
Shares Trade Date
Encore Energy Partners LP
ENP UBS Investment Bank
Lehman Brothers $20.00-$22.00
9.0 mil Week of 9/10
ZARS Pharma
ZARS Cowen & Company
CIBC World Markets $14.00-$16.00
5.0 mil Week of 9/17
Liberty Acquisition Holdings*
LIA.U Citi
Lehman Brothers $10.00-$10.00
75.0 mil Week of 10/1
Merrion Pharmaceuticals
MERR Punk Ziegel
Goodbody $0.00-$0.00
0.0 mil Week of 10/1
IPO Quiet Period Dates
Upcoming IPO Quiet Period Dates
Company Name Symbol Offer Date Lead Underwriter Quiet Period Expires
Alternative Asset Management Acquisition AMV-U 8/1/07 Citi 9/10/07
Dolan Media DM 8/1/07 Goldman Sachs 9/10/07
Genpact Limited G 8/1/07 Morgan Stanley 9/10/07
Sucampo Pharmaceuticals SCMP 8/1/07 Cowen & Company 9/10/07
Concho Resources CXO 8/2/07 J.P. Morgan 9/11/07
Virtusa VRTU 8/2/07 J.P. Morgan 9/11/07
Quicksilver Gas Services LP KGS 8/6/07 UBS Investment Bank 9/15/07
E-House (China) Holdings EJ 8/7/07 Credit Suisse 9/16/07
HireRight HIRE 8/7/07 Credit Suisse 9/16/07
Masimo Corporation MASI 8/7/07 Piper Jaffray 9/16/07
DemandTec DMAN 8/8/07 Morgan Stanley 9/17/07
WuXi PharmaTech WX 8/8/07 Credit Suisse 9/17/07
Horsehead Holding ZINC 8/9/07 Friedman Billings 9/18/07
MercadoLibre MELI 8/9/07 J.P. Morgan 9/18/07
Paragon Shipping PRGN 8/9/07 UBS Investment Bank 9/18/07
VMware VMW 8/13/07 Citi 9/22/07
Cosan Limited CZZ 8/15/07 Credit Suisse 9/24/07
Financial services firm Duff & Phelps announces terms
9/5/2007
Duff & Phelps, which provides independent financial advisory and investment banking services, filed terms Tuesday with the SEC for its upcoming IPO. The company plans to offer 8.3 million shares at a price range of $16.50 to $18.50. Goldman Sachs and UBS are the joint book runners on the deal.
http://www.ipohome.com/marketwatch/iponews.asp
Electronic materials provider Rubicon Technology files for an IPO
9/5/2007
Rubicon Technology, which develops, manufactures, and sells monocrystalline sapphire and other innovative crystalline products, filed for an IPO Wednesday with the SEC. The company filed to be listed on the NASDAQ under the ticker "RBCN." UBS is the lead manager on the deal. No terms were disclosed in the initial filing.
http://www.ipohome.com/marketwatch/iponews.asp
SPPI- I noted that one as soon as the seasonal stocks were listed. Me like.
Hoooooooooooooooray!!!!!!!!!!!!!
****FAT CATS POSTER OF THE WEEK-----------------
CONGRATULATIONS SMOKINTEK!!!!!
http://investorshub.advfn.com/boards/profile.asp?user=77499
Your posts are the exact touch of what we need during these highs and lows
of everyday and of market swings.
We've not had such a humerous and wild poster like you,
ever in the history of ihub.
Every post of yours is exciting and most often, very funny.
Hats off to you, Smokey Dokey.
You're one of a kind!!!
PS- Thanks to the posters of Fat Cats...
Smokey, You had the MOST nominations in the history of the honor roll for every reason mentioned. People dig you here, it's your home.
Have a great day :)
ZILA 1.20 (note: thinly traded ) Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
Tuesday September 4, 7:35 am ET
- ViziLite Plus with TBlue630 -
PHOENIX, Sept. 4 /PRNewswire-FirstCall/ -- Zila, Inc.'s (Nasdaq: ZILA - News) ViziLite® Plus with Tblue630(TM) screening system for early detection of abnormalities which can lead to oral cancer, has been selected to identify pre-cancerous lesions in a Phase II study of Cetuximab (ERBITUX®), a leading cancer therapeutic for head and neck cancer developed by ImClone Systems (Nasdaq: IMCL - News) and distributed by Bristol-Meyers Squibb (NYSE: BMY - News).
The NIH has awarded a Specialized Program of Research Excellence (SPORE) grant for the study. The primary objective of the clinical trial is to evaluate ERBITUX efficacy in treating upper aerodigestive pre-cancer. ERBITUX is currently marketed for the treatment of head and neck cancer (including upper aerodigestive) as well as metastatic colorectal cancer.
Dr. Frank J.Bellizzi, President of Zila Pharmaceuticals, "We are pleased that Zila's ViziLite Plus with Tblue630 has been selected for use in this clinical trial. The use of ViziLite Plus in such an important study with the leading head and neck cancer therapeutic demonstrates its growing reputation as the premier oral cancer screening technology."
The coordinating center for the study is The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. The Protocol Chairman is Joseph Califano, M.D., of the Department of Otolaryngology-Head and Neck Surgery.
Over 30 clinical investigators at key academic research institutions and cancer research centers are scheduled to participate in the study. The Phase II study is anticipated to enroll and evaluate approximately 60 patients over a three-year period. Patients will be evaluated clinically and biopsies will be taken pre- and post-treatment. The biopsies will be analyzed histopathologically, but will also be analyzed for genetic changes using Zila's proprietary LOH assay. The assay is the only validated method for identifying biomarkers consistent with oral premalignencies and oral cancer.
About ViziLite® Plus
ViziLite® Plus is an oral screening technology that utilizes ViziLite, an advanced chemiluminescent light technology, with Tblue630. The Tblue630 marking system employs Zila Tolonium Chloride (ZTC(TM)), the only patented pharmaceutical-grade form of toluidine blue in an FDA-cleared device.
For more information about ViziLite Plus, visit http://www.vizilite.com.
About Zila's LOH Assay
Biopsies are traditionally analyzed histopathologically to determine the histological changes in diseased tissue and enable classification of the tissue such as benign, dysplastic or cancerous. Leading cancer centers now recognize the value of also evaluating the DNA of biopsy samples for markers that signal that tissue is on the progression pathway to cancer. Zila has developed a proprietary DNA assay that evaluates chromosomal deletions by determining the loss of heterozygosity (LOH) of such biopsies. The validated LOH assay is utilized in the Zila OraTest Phase III clinical trial as well as the Erbitux Study, and the Company is evaluating commercial opportunities for the test.
About Zila, Inc.
Zila, Inc., headquartered in Phoenix, is an oral cancer screening company focused on the prevention and treatment of oral disease. Zila is dedicated to establishing ViziLite® Plus as the new standard of care for the early detection of oral abnormalities that could lead to cancer, with an initial focus on the dental market through Pro-Dentec®, a leading designer, manufacturer and marketer of Soft Tissue Management (STM®) products. Sold exclusively and directly to dental professionals, Pro-Dentec's core products include the Rota-dent® Professional Powered Brush, the Pro-Select3® Piezo-Ultrasonic Scaler System and a suite of pharmaceutical STM® products for both in-office and home-care use.
For more information about Zila, visit http://www.zila.com.
--------------------------------------------------------------------------------
Source: Zila, Inc.
http://biz.yahoo.com/prnews/070904/latu045.html?.v=101
MDCO: 16.70 CORRECTING and REPLACING Angiox(R) (Bivalirudin) Alone Reduced Early Bleeding and Resulted in Similar One-Year Mortality Compared to Heparins Plus GP IIb/IIIa Combination Therapy in ACS Patients Undergoing Angioplasty
Monday September 3, 2:14 pm ET
Results Were Consistent in Patients Switched to Angiox from Other Antithrombin Therapy
VIENNA, Austria--(BUSINESS WIRE)--Please replace the release dated September 2, 2007 with the following corrected version due to multiple revisions.
The corrected release reads:
ANGIOX® (BIVALIRUDIN) ALONE REDUCED EARLY BLEEDING AND RESULTED IN SIMILAR ONE-YEAR MORTALITY COMPARED TO HEPARINS PLUS GP IIB/IIIA COMBINATION THERAPY IN ACS PATIENTS UNDERGOING ANGIOPLASTY
ADVERTISEMENT
Results Were Consistent in Patients Switched to Angiox from Other Antithrombin Therapy
Patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), or angioplasty, experienced nearly 50 percent less bleeding at 30 days and comparable mortality at one-year when treated with Angiox® (bivalirudin) alone compared to unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor (GPI), according to data from the ACUITY trial. These findings were consistent in patients switched to Angiox monotherapy from unfractionated heparin or enoxaparin. These data were presented today at the European Society of Cardiology (ESC) Congress 2007. The Medicines Company (NASDAQ: MDCO - News) recently re-acquired rights for Angiox in Europe and currently markets the product as Angiomax® in the United States.
"The ACUITY trial demonstrated that Angiox is the preferred antithrombotic strategy in moderate and high risk ACS patients undergoing PCI. The subgroup analysis presented today gives us compelling new information on the benefits of switching ACS patients to Angiox," said lead author of the study, Harvey D. White, MD, Director of Coronary Care and Cardiovascular Research at Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand. "The reduction in early bleeding achieved with Angiox monotherapy is particularly important, as bleeding events are commonly linked to late mortality in these patients."
The ESC recently published guidelines for the treatment of ACS that recommend using Angiox to replace heparins (unfractionated or low-molecular weight) and GPIs in ACS patients undergoing PCI.
Study Details
The subgroup analysis of the ACUITY trial in ACS patients undergoing PCI presented today are consistent with the overall ACUITY results. As previously reported, in ACS patients undergoing PCI, the risk of major bleeding at 30 days was significantly less - by nearly 50 percent - in patients who received Angiox alone compared to those who received unfractionated heparin or enoxaparin plus GPI: 4% vs. 7% (p less than 0.0001).(1) In his presentation at ESC, Dr. White showed that the clinical benefits of Angiox monotherapy compared to unfractionated heparin or enoxaparin plus GPI were consistent across subgroups of patients, including those at high-risk, those who received other previous antithrombin therapy and were switched to Angiox, and those who did not receive prior antithrombin therapy. Additionally, the new analysis showed that, after one year, there were no significant differences in the incidence of composite ischemic events or mortality between patients who had received Angiox monotherapy and those who had received unfractionated heparin or enoxaparin plus GPI. The mortality results observed at one-year with Angiox monotherapy were not dependent on the timing of clopidogrel administration. PCI patients experiencing a non-CABG (coronary artery bypass graft) major bleed had a significantly longer length of hospital stay, 5.0 days vs. 3.0 days (p less than 0.0001), compared with those that did not bleed. Further, a strong association was observed between bleeding events at 30 days and one-year mortality in ACS patients undergoing PCI.
About ACUITY
ACUITY was one of the largest ACS clinical trials ever conducted to evaluate anti-thrombotic therapies and enrolled 13,819 high-risk patients in 450 centers worldwide. The trial design employed an early invasive strategy (angiography within 72 hours), starting anti-clotting therapy when ACS patients arrived at the emergency department and randomly assigning them to treatment with standard therapy of heparin (unfractionated or enoxaparin) plus GPI, Angiox plus GPI, or Angiox monotherapy. In the Angiox monotherapy group, selective use of GPI was permitted in limited circumstances and occurred in less than 10% of patients. Then, based on an evaluation in the cardiac catheterization laboratory, patients were treated for ACS through medical management, bypass surgery or PCI.
About Angiox/Angiomax
Angiox/Angiomax is currently approved in the European Union and the United States as well as several other territories. It is a direct thrombin inhibitor with a naturally reversible mechanism of action. In clinical trials, Angiox has demonstrated efficacy plus reductions in bleeding complications compared to heparin as the foundation anticoagulant in the contemporary catheterization lab setting. These reductions in bleeding complications remain evident even in high-risk patients.
In Europe, Angiox is indicated as an anticoagulant for patients undergoing PCI. Please see full prescribing information available at http://www.angiox.com.
European regulatory authorities are currently reviewing an application to expand the use of Angiox to include the emergency use of Angiox in ACS patients undergoing PCI.
MDCO-G
About The Medicines Company
The Medicines Company meets the demands of the world's most advanced medical practitioners by developing products that improve acute hospital care. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. In July 2007 the Company terminated its distribution arrangements with Nycomed and reacquired from Nycomed all development, commercial and distribution rights held by Nycomed for Angiox® (bivalirudin) in Europe. The Company also has two products in late-stage development, Cleviprex(TM) (clevidipine) and cangrelor. The Company's website is http://www.themedicinescompany.com.
Statements contained in this press release about The Medicines Company and Angiomax®/Angiox® that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates," "expects," "estimates," "projects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Important factors that may cause or contribute to such differences include whether clinical trial results of the Company's product candidates will warrant submission of applications for regulatory approval on a timely basis or at all; whether the Company's product candidates will receive approvals from regulatory agencies on a timely basis or at all; and whether physicians will accept clinical trial results. Such factors and others are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on August 9, 2007, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
(1) Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW; Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007 Mar 17;369(9565):907-19.
Contact:
Investors:
The Medicines Company
Michael Mitchell, 973-656-1616
Executive Director, Corporate Affairs
investor.relations@themedco.com
or
Media:
Biosector 2
Sloane Occhiuto, 212-845-5633
socchiuto@biosector2.com
--------------------------------------------------------------------------------
Source: The Medicines Company
http://biz.yahoo.com/bw/070903/20070902005040.html?.v=2
QLTI Chart-leap in vol yesterday- great news this am:
QLTI: 5.92 (moving p/m) Eligard(R) six-month formulation successfully completes European approval procedure
Friday August 31, 2:41 am ET
VANCOUVER, Aug. 31 /PRNewswire-FirstCall/ - QLT USA, Inc., a subsidiary of QLT Inc. (NASDAQ: QLTI - News; TSX: QLT - News), announced today that the European approval procedure for the Eligard® 45 mg six-month formulation was successfully completed. Launch of this formulation in 23 European countries is expected to follow the implementation of this positive decision in each of the individual countries. The 6-month formulation was launched in Germany in March 2007 following its approval in December 2006. Eligard is already approved in Germany and other European countries for the one-month (7.5 mg) and three-month (22.5 mg) formulations.
"The six-month formulation provides physicians with a new convenient option for patients with prostate cancer," said Bob Butchofsky, President and Chief Executive Officer of QLT Inc. "Eligard sales have been strong recently and we believe that this new approval will help contribute to future product growth."
Through the first six months of 2007, Eligard worldwide sales have been approximately US$86.4 million. Based on the strong trend in Eligard sales during the first half of the year in July the Company raised its annual guidance on Eligard sales to project a range of US$160 million to US$180 million, an increase over previously announced guidance of US$140 million to US$160 million.
About Eligard
Eligard, a palliative treatment for advanced prostate cancer, incorporates a luteinizing hormone-releasing hormone agonist, or LHRH agonist, known as leuprolide acetate with QLT USA's proprietary Atrigel® Delivery System. The Atrigel technology allows for sustained delivery of leuprolide acetate for periods ranging from one to six months.
Eligard works by lowering the levels of testosterone in the body, which may result in a reduction of symptoms related to the disease. Sustained levels of leuprolide decrease testosterone levels to suppress tumor growth in patients with hormone-responsive prostate cancer. The liquid Eligard products are injected subcutaneously with a small gauge needle, forming a solid implant in the body that slowly releases leuprolide as the implant is bioabsorbed.
About QLT
QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize two unique technology platforms, photodynamic therapy and Atrigel®, to create products such as Visudyne® and Eligard®. For more information, visit our web site at www.qltinc.com.
Atrigel is a registered trademark of QLT USA, Inc.
Visudyne is a registered trademark of Novartis AG.
Eligard is a registered trademark of Sanofi-aventis.
QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."
Certain statements in this press release constitute "forward-looking statements" of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of the Securities Act (Ontario). Such statements include, but are not limited to, the statement with respect to our belief that the successful completion of the European approval procedure will contribute to future product growth, our expectations as to the launch of the six-month formulation in 23 other European countries, the statement projecting Eligard annual sales, and statements containing words such as "expects," "believes," "potential" and similar expressions that do not relate to historical matters. These forward-looking statements are only predictions which involve known and unknown risks, uncertainties and other factors that may cause actual events or results to differ materially. Factors that could cause actual events or results to differ materially include, but are not limited to: the risk that Astellas may be unsuccessful in its efforts to market the six-month formulation of Eligard; the anticipated market potential for Eligard may not be realized; the outcome of the appeal in German patent litigation commenced by Takeda Chemical Industries Ltd. and Wako Pure Chemical Industries, Ltd. against Astellas and Medigene in Germany with respect to Eligard may be unfavorable and could result in QLT USA, Inc. being required to pay financial damages which could be substantial; and other risk factors which are described in detail in QLT's Annual Information Form on Form 10-K, quarterly reports on Form 10-Q, Registration Statement on Form S-4 and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are based on our current expectations and QLT does not assume any obligation to update such information to reflect later events or developments, except as may be required by law.
CONTACT: QLT Inc.: Vancouver, Canada, Therese Hayes, Telephone: (604) 707-7000 or 1-800-663-5486, Fax: (604) 707-7001
--------------------------------------------------------------------------------
Source: QLT Inc.
http://biz.yahoo.com/prnews/070831/to409.html?.v=23
Churak, a fine example would be the casting of the Ihub movie based on the photo gallery:
http://investorshub.advfn.com/boards/board.asp?board_id=4299
Well lookit that. Do I see any gaps in there that have to fill?
that is one wild cabaret ticker
BDCO Chart:
AFTERHOURS: BDCO: 3.80 Blue Dolphin Energy Company Subsidiary Enters Into New Pipeline Transportation Agreement
Wednesday August 29, 6:18 pm ET
HOUSTON, Aug. 29 /PRNewswire-FirstCall/ -- Blue Dolphin Energy Company (Nasdaq: BDCO - News; "Blue Dolphin"), an independent oil and gas company with operations in the Gulf of Mexico, today announced that its wholly-owned subsidiary, Blue Dolphin Pipe Line Company, has contracted with a new shipper to provide gas and condensate transportation services for the shipper's production to be delivered into the Galveston Area Block 350 Pipeline. The production will be delivered into the pipeline in Galveston Area Block 350. The Company expects transportation services for this shipper to commence during the third quarter 2007. Throughput volumes are not yet known. Blue Dolphin Pipe Line Company owns an 83% undivided interest in the Galveston Area Block 350 Pipeline.
Blue Dolphin Energy Company is engaged in the gathering and transportation of natural gas and condensate and production of oil and gas. For further information visit the Company's website at http://www.blue-dolphin.com.
Certain of the statements included in this press release, which express a belief, expectation or intention, as well as those regarding future financial performance or results, or which are not historical facts, are "forward-looking" statements as that term is defined in the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. The words "expect", "plan", "believe", "anticipate", "project", "estimate", and similar expressions are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance or events and such statements involve a number of risks, uncertainties and assumptions, including but not limited to industry conditions, prices of crude oil and natural gas, regulatory changes, general economic conditions, interest rates, competition, and other factors. Should one or more of these risks or uncertainties materialize or should the underlying assumptions prove incorrect, actual results and outcomes may differ materially from those indicated in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
--------------------------------------------------------------------------------
Source: Blue Dolphin Energy Company
http://biz.yahoo.com/prnews/070829/law128.html?.v=46
**RANDOM ACT OF KINDNESS update----
dounome
http://investorshub.advfn.com/boards/profile.asp?user=62730
is currently KEEPING US WAITING. We are UNSURE at this moment
what scenario has concealed his MONSTER stock pick.
I think a madman pinned him to an alley garbage can and perhaps
threatening him for his tip!! He must have obeyed or his future would be blacklisted and accounts would be
liquidated into an off-shore penny mob's family estate.
Perhaps he's teamed up with Leona Helmsley's 12 million dollar dog and is trading for Trouble as we speak.
What's in a name? GLTY Dounome. Good luck.
---------------------------
Posted by: dounome
In reply to: xbigshot1 who wrote msg# 1073268 Date:8/27/2007 8:00:39 PM
Post #of 1075139
Xman understand this,this is not a pump its an opportunity
you can look at the post or don't bother its your choice.
This is a RANDOM ACT OF KINDNESS.Be here in two days or
don't,everyone is not lucky and sometimes when opportunity knocks some people just won't get up and answer the door.
WHAT WILL YOU DO!
Well, although the news AH doesn't release specific numbers, it does resign to a commitment for the next 5 years.
Wall St rallies led by tech stocks
By Hal Weitzman in New York
Wednesday Aug 29 2007 16:30
Wall Street stocks rebounded strongly on Wednesday after sharp falls in the leading indices on Tuesday.
Markets were lifted by the release of a letter from Ben Bernanke, chairman of the Federal Reserve, to Charles Schumer, chairman of Congress's Joint Economic Committee, saying the Fed is closely watching financial markets and is "prepared to act as needed" should the economy be threatened.
Shares were also bolstered by a resurgent technology sector, Altria's long-awaited spin-off of Philip Morris International and some better-than-expected earnings results.
http://us.ft.com/ftgateway/superpage.ft?news_id=fto082920071641190942
Altria to split up Philip Morris
By Christopher Bowe in New York
Wednesday Aug 29 2007 19:30
Altria Group (NYSE:MO) on Wednesday said it would split the international and domestic operations of Philip Morris, the world's biggest cigarette maker, into separate public companies in a long-anticipated move.
The fast-growing international unit, Philip Morris International, will be spun off to shareholders, severing it from Philip Morris USA, which is suffering from falling US cigarette consumption. The spin-off is set for next year after a unanimous board vote. Timing will be given on January 30.
http://us.ft.com/ftgateway/superpage.ft?news_id=fto082920071941510981&referrer_id=yahoofinance
Stocks Rebound on Bargain Hunting
Wednesday August 29, 7:11 pm ET
By Madlen Read, AP Business Writer
Stocks Surge As Wall Street Goes Hunting for Bargains, Anticipates Rate Cut
NEW YORK (AP) -- Stocks rebounded sharply Wednesday as investors, growing more optimistic about chances for an interest rate cut, sought bargains after the previous session's huge tumble. The Dow Jones industrials gained almost 250 points.
Many investors believe the Federal Reserve will cut interest rates at its next meeting on Sept. 18 or even sooner and were preparing for Fed Chairman Ben Bernanke to hint at such a move on Friday at a speech in Jackson Hole, Wyo. The possibility of a rate cut has given Wall Street some hope that the stock market will recover from its summer volatility, and that right now, it's a good strategy to buy while the buying is cheap.
News that Bernanke said in a letter to Sen. Charles Schumer, D-N.Y., that Fed policymakers are "prepared to act as needed" if the market's turbulence hurts the economy helped pad the market's gain.
The Fed, although it has not yet indicated that it will indeed lower the benchmark fed funds rate, has been adding cash to the banking system in an attempt to keep the credit markets liquid. The Federal Reserve Bank of New York said Wednesday it would inject $5.25 billion through a one-day repurchase agreement, where it buys that amount in collateral from dealers who then deposit the money into commercial banks.
Wall Street was also enthusiastic about signs of corporate muscle. A jump in oil prices fed a rally in energy company stocks, and positive news from technology companies including Seagate Technology gave that sector a boost. Meanwhile, Altria Group Inc. spun off its Philip Morris International cigarette business.
Stock investors kept an eye on the credit markets for signs of loosening. Though the safest assets, Treasurys, are not seeing the same frantic buying they saw a couple weeks ago, assets with a bit more risk, like commercial paper, are having some trouble attracting buyers.
"Everyone's waiting for the dust to settle there," said Steven Goldman, chief market strategist at Weeden & Co. "We're on a little bit better footing, but we're in a healing process that takes time." He added that he regards a Fed rate cut as "mandatory."
The Dow rose 247.44, or 1.90 percent, to 13,289.29, near its highs of the session. The blue chip index tumbled 280 points on Tuesday amid pessimism about the Fed's intentions.
Broader stock indicators also jumped. The Standard & Poor's 500 index added 31.40, or 2.19 percent, to 1,463.76, while the Nasdaq composite index gained 62.52, or 2.50 percent, to 2,563.16.
Bonds fell back as investors moved back into stocks. The yield on the benchmark 10-year Treasury note rose to 4.57 percent from 4.52 percent late Tuesday.
Light, sweet crude soared $1.78 to $73.51 a barrel on the New York Mercantile Exchange after the U.S. Energy Department reported larger-than-expected declines in gasoline and oil inventories.
One reason for Wednesday's triple-digit rebound -- with some 100 points gained in the final hour of trading alone, is that volume again is light -- which tends to skew the market's movements. Advancing issues led decliners by about 5 to 1 on the New York Stock Exchange, where consolidated volume came to 2.77 billion compared to 2.35 billion on Tuesday.
Volatility has returned to the market this week after last week's relative calm. Investors on Tuesday sent shares sharply lower on further concerns about the strength of the economy and whether the Fed will act in an effort to prevent credit troubles from spreading further.
Michael Sheldon, chief market strategist at Spencer Clarke, said he believes investors are positioning themselves ahead of Bernanke's speech. He believes the rebound during the session shows that perhaps investors are becoming more confident the Fed will lower interest rates and that financial institutions can weather their exposure to distressed mortgages and loans.
"At least for a day, people feel like there is a light at the end of the tunnel," he said. "The problems facing the big brokerage firms, while not great, are being seen as at least manageable."
Bear Stearns Cos. fell $1.32 to $107.10, Lehman Brothers Holdings Inc. rose 15 cents to $54.43, and Goldman Sachs Group Inc. was up $2.77 at $173.72.
The technology sector was strong, helping to boost the Nasdaq, after several analysts raised their price targets on Seagate Technology in response to its improved fiscal first-quarter outlook. Seagate rose $1.04, or 4.2 percent, to $25.50.
Nokia Corp. was another standout in tech, after it unveiled new Internet services and gadgets for downloading music and playing games on mobile handsets. Nokia rose $1.17, or 7.3 percent, to $32.70.
The retail sector also lured buyers, after down-market Big Lots Inc. and up-market Williams-Sonoma Inc. raised their outlooks -- a good sign that companies don't foresee a significant decline in consumer spending.
Williams-Sonoma rose $3.13, or 10.6 percent to $32.70, while Big Lots rose $2.61, or 9.9 percent, to $28.91.
The housing market outlook remains weak, though. Mortgage application volume, refinance volume and purchase volume all fell about 4 percent during the week ended Aug. 24 compared to the prior week, according to the Mortgage Bankers Association's weekly application survey.
The Russell 2000 index of smaller companies rose 19.49, or 2.54 percent, to 787.32.
The dollar fell against other major currencies except the yen. Gold prices rose.
Wall Street's plunge Tuesday triggered selling in Asia. Japan's Nikkei stock average fell 1.69 percent, Hong Kong's key index fell 1.5 percent, and China's Shanghai Composite Index fell 1.64 percent. European markets, however, advanced. Britain's FTSE 100 rose 0.49 percent, Germany's DAX index rose 0.12 percent, and France's CAC-40 rose 0.84 percent.
New York Stock Exchange: http://www.nyse.com
Nasdaq Stock Market: http://www.nasdaq.com
http://biz.yahoo.com/ap/070829/wall_street.html?.v=47
NIS Chart (3.81)
Thanks Tiki!
Cool. I just posted the news and to be honest hadn't scanned the board for double post of it yet.
AFTERHOURS: FRPT: Infiniti Stocks To Watch:
Force Protection, Inc. Ahead of MRAP Vehicle Production Schedule
Wednesday August 29, 4:15 pm ET
LADSON, S.C.--(BUSINESS WIRE)--Leading armored vehicle manufacturer Force Protection, Inc. (Nasdaq:FRPT - News) today announced that it is ahead of its Mine Resistant Ambush Protected (MRAP) production schedule for the month of August. The company has produced more than 50 Cougar vehicles to support the U.S. Department of Defense MRAP program. The Category II Cougar 6x6 vehicle commitment for August has already been shipped.
"We have not yet closed August and are well ahead of our production objectives," said Force Protection COO Raymond Pollard. "This is indicative of the efficiencies of our proven manufacturing processes that are producing a proven solution which has effectively countered more than 3,000 mine detonations and IED attacks in the past four years."
The Pentagon has awarded Force Protection contracts for more than 1,900 Cougar and Buffalo vehicles to support its Category I, II, and III MRAP program requirements.
"This is also reflective of the fact that our efforts to mobilize industry resources through our partnering agreements are having their intended effects," added Pollard. "We will continue to do everything necessary to meet the needs of our customers and the men and women who depend on these vehicles."
Force Protection's Cougar and Buffalo vehicle series have been deployed in Iraq and Afghanistan since 2003. They have become the gold standard for troop safety, and their proven performance has formed the basis for the MRAP vehicle program. In addition to its own production capacity, Force Protection has created a joint venture with General Dynamics Land Systems to increase both capacity and deliveries under its MRAP program awards.
About Force Protection Inc.
Force Protection, Inc., first to answer the call to duty for the urgent need to bring lifesaving mine-resistant ambush protected vehicles to U.S. troops in combat and an American company whose vehicles, Cougar and Buffalo, have a proven track record where it matters most; in the battlefield, manufactures ballistic- and mine-protected vehicles through its wholly-owned subsidiary. These specialty vehicles protect against landmines, hostile fire, and Improvised Explosive Devices (IEDs, commonly referred to as roadside bombs). Force Protection's mine and ballistic protection technologies are among the most advanced in the world. The vehicles are manufactured outside Charleston, S.C. For more information on Force Protection and its vehicles, visit www.forceprotection.net.
About General Dynamics
General Dynamics Land Systems, a business unit of General Dynamics (NYSE:GD - News), is headquartered in Falls Church, Va., employs approximately 82,900 people worldwide and anticipates 2007 revenues of approximately $27 billion. The company has leading market positions in mission critical information systems and technologies, land and amphibious combat systems, shipbuilding and marine systems, and business aviation. More information about the company is available on the Internet at www.generaldynamics.com.
This press release contains forward-looking statements that involve risks and uncertainties. The Company generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. You should not place undue reliance on these forward-looking statements. Actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including the risks described in the Company's Form 10-K and other reports filed with the Securities and Exchange Commission. Although management believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and the Company's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in expectations, except as required by law.
Contact:
Policy Impact Communications
Jeff Child, 202-737-5339
--------------------------------------------------------------------------------
Source: Force Protection, Inc.
http://biz.yahoo.com/bw/070829/20070829005954.html?.v=1
SWC Chart:
AFTERHOURS: SWC: 8.89 Stillwater Mining Company Signs New PGM Supply Agreements
Wednesday August 29, 6:34 pm ET
Shares Outstanding: 92.22M
Float: 36.70M
BILLINGS, Mont., Aug. 29 /PRNewswire-FirstCall/ -- Stillwater Mining Company (NYSE: SWC - News) announced today that it has amended the provisions of an existing PGM supply agreement and has signed a new agreement with one of its existing automotive industry customers extending a portion of Stillwater's sales commitments through 2012.
The terms of the new agreements include:
-- Stipulated monthly delivery commitments for palladium and rhodium;
-- Some sourcing flexibility for Stillwater on palladium and rhodium
deliveries;
-- A guaranteed minimum floor price on all sales of palladium under the
agreement; and
-- A customer discount off the prevailing market price on all sales above
the floor price.
The agreement also provides the customer with an opportunity to elect increased delivery volumes of palladium and rhodium after 2010.
Stillwater Mining Company is the only U.S. producer of palladium and platinum and is the largest primary producer of platinum group metals outside of the Republic of South Africa and the Russian Federation. The Company's shares are traded on the New York Stock Exchange under the symbol SWC. Information on Stillwater Mining can be found at its Website: http://www.stillwatermining.com.
--------------------------------------------------------------------------------
Source: Stillwater Mining Company
http://biz.yahoo.com/prnews/070829/law131.html?.v=35
that was you? I saw someone waving from a plane and I called the tower control. I didn't know you were just saying hello to Serf. Whoops. My bad.
Asian Stocks Dip on Wall Street Fall
Tuesday August 28, 10:56 pm ET
Asian Stocks Dip on Heels of Wall Street Fall
TOKYO (AP) -- Asian stocks fell sharply Wednesday on the heels of a decline on Wall Street, where investors remained uneasy over global credit markets and there were more worries about consumer confidence and falling home prices.
Japan's benchmark Nikkei 225 index had plunged 2.59 percent by the end of Tokyo's morning session, while benchmarks in South Korea and New Zealand lost as much as 3.1 percent and 1.4 percent, respectively, in morning trading.
The Korea Composite Stock Price Index recovered slightly from its morning lows and was down 1 percent at 1,811.17 by midday. New Zealand's NZX-50 index was down 0.9 percent at 4,063.28.
Major indices in China, Hong Kong, the Philippines, Singapore and Taiwan also lost ground.
In Tokyo, traders sold exporter issues on the weak dollar, which was trading at 114.06 yen midmorning, down from 114.56 yen late Tuesday in New York, as the renewed market volatility had investors backing away from risky yen-carry trades. To exit the trades, investors have to buy yen to repay cheap yen loans.
The stronger yen makes Japanese exports more expensive and less competitive overseas.
Among the early decliners were Toyota Motor Corp., which lost 3 percent, and Nissan Motor Co., which fell 3.9 percent.
In South Korea, Samsung Electronics Co., the country's biggest corporation, fell 2.4 percent, and Hyundai heavy Industries Co., the world's largest shipbuilder, declined 1.3 percent.
In New York on Tuesday, the Dow Jones industrial average fell 280.28, or 2.10 percent, to 13,041.85, its biggest drop since Aug. 9. Broader stock indicators, including the Standard & Poor's 500 index, also fell.
http://biz.yahoo.com/ap/070828/asia_markets.html?.v=3
HOKU! HOKU! (sounds like coughing) In the sea of red, it seems to have faired well today.........no news: